Skip to main content
. 2015 Jan 12;27(1):85–96. doi: 10.1016/j.ccell.2014.11.006

Figure 4.

Figure 4

CCT196969 and CCT241161 Inhibit Tumors with Acquired Resistance to Vemurafenib

(A) pERK and pSFK in pre- and postvemurafenib treatment tumors from patient #3. Scale bars, 50 μm.

(B) Patient #3 tumor cell proliferation assay (CellTiter Glo) with PLX4720, CCT196969, and CCT241161.

(C) pERK, ERK2, and pSFK in patient #3 PDX in mice treated with PLX4720, CCT196969, or CCT241161.

(D) Growth of patient #3 PDX in NSG mice treated with PLX4720, CCT196969, or CCT241161.

(E) pERK and pSFK in pre- and post-vemurafenib treatment tumors from patient #4. Scale bars, 100 μm.

(F) Growth of patient #4 PDX in NSG mice treated with PLX4720, CCT196969, or CCT241161 21 days after tumor implant. ∗∗∗p ≤ 0.001 (t test, two-tailed).

Bars represent SEM. See also Figure S4.